


Top 5 stocks traded by our customers Mar 2025

EQUITY STRATEGY TEAM

SG Market




*The Top 5 stocks are based on total traded value by OSPL customers for the month. Ranking as of 31 Mar 2025. All data and information extracted from Bloomberg as of 01 Apr 2025 closing unless otherwise stated. Trendlines drawn on price charts are a visual representation of support & resistance levels. They are drawn by connecting a series of prices together to help indicate the data's best fit or the presence of any trend over a time frame, and are for illustration purposes only. Only companies with Market cap above SGD 200million will be considered.

	Quick Stock Highlights	Technical Levels & Charting
<p>1 DBS</p>	<ul style="list-style-type: none"> DBS regards Shenzhen Rural Commercial Bank as a "strategic" asset, and would remain a major shareholder if the Chinese lender decides to list as a public company [28 Mar 2025, Reuters] DBS is the frontrunner to buy a controlling stake in Indonesia's Panin Bank. Roughly 86% of Panin Bank, Indonesia's 12th largest lender, is up for sale [26 Mar 2025, Reuters] 	
<p>2 UOB</p>	<ul style="list-style-type: none"> UOB launched its 11th Foreign Direct Investment (FDI) Advisory Centre in Seoul, expanding its support for South Korean businesses entering the Association of Southeast Asian Nations (ASEAN) [28 Mar 2025, MT Newswires] UOB said it intends to issue US\$2 billion in a US dollar-denominated multi-tranche bond due 2028 and 2030 [27 Mar 2025, Reuters] 	
<p>3 Singapore Tech Engineering</p>	<ul style="list-style-type: none"> Singapore Technologies Engineering forms joint venture with HTX to develop and maintain capabilities for mission-critical systems [26 Mar 2025, Reuters] Singapore Technologies Engineering's growth outlook appears upbeat with its aggressive 2029 targets. According to management, the technology, defense and engineering group targets revenue CAGR of 2X global GDP growth rate to S\$17 billion by 2029 [21 Mar 2025, Dow Jones Newswires] 	
<p>4 Yangzijiang Shipbuilding</p>	<ul style="list-style-type: none"> Yangzijiang Shipbuilding completed a capital injection to acquire a 34% equity stake in Tsuneishi Group (Zhoushan) Shipbuilding, a subsidiary of Tsuneishi Holdings [25 Mar 2025, MT Newswires] Yangzijiang Shipbuilding Holdings shares dropped 27 Feb 2025 after the company warned that proposed US fees on Chinese ships could affect new orders in the near term [27 Feb 2025, Dow Jones Newswires] 	
<p>5 Singapore Airlines</p>	<ul style="list-style-type: none"> Singapore Airlines confirms Singapore to London Heathrow Flights affected by Heathrow closure [21 Mar 2025, Reuters] Singapore Airlines and Scoot passengers will not be allowed to use power banks to charge their devices during flights [12 Mar 2025, CNA] 	

Top 5 stocks traded by our customers Mar 2025

EQUITY STRATEGY TEAM

US Market




*The Top 5 stocks are based on total traded value by OSPL customers for the month. Ranking as of 31 Mar 2025. All data and information extracted from Bloomberg as of 01 Apr 2025 closing unless otherwise stated. Trendlines drawn on price charts are a visual representation of support & resistance levels. They are drawn by connecting a series of prices together to help indicate the data's best fit or the presence of any trend over a time frame, and are for illustration purposes only.

	Quick Stock Highlights	Technical Levels & Charting
<h1>1</h1> <h2>Nvidia</h2>	<ul style="list-style-type: none"> Nvidia, a major player in the AI industry, is facing a significant market challenge following the public debut of cloud computing firm CoreWeave (01 Apr 2025, Bloomberg) OpenAI and Oracle plan to begin filling a massive new data center in Texas with tens of thousands of powerful AI chips from Nvidia in the coming months, part of a push to get the first facility for their US\$100 billion Stargate infrastructure venture up and running (07 Mar 2025, Bloomberg) 	
<h1>2</h1> <h2>Tesla</h2>	<ul style="list-style-type: none"> With its showrooms vandalized, production lines paused and sales tanking overseas, Tesla Inc. has had a brutal start to 2025 (01 Apr 2025, Bloomberg) Tesla's sales fell for the 10th time in the last 12 months in Europe, where Elon Musk's politicking and a changeover of the carmaker's most important product have been major hindrances (25 Mar 2025, Bloomberg) Tesla tumbled, while BYD Co shot to an all-time high after unveiling an electric car that can be charged as quickly as a gas vehicle is refueled (19 Mar 2025, Bloomberg) 	
<h1>3</h1> <h2>Palantir</h2>	<ul style="list-style-type: none"> Palantir Technologies has sued Y Combinator-backed startup Guardian AI and its founders for what it called "brazen" trade secret theft in the U.S. District Court for the Southern District of New York (02 Apr 2025, Bloomberg) Palantir Technologies and R1 have launched R37, an artificial intelligence lab that aims to offer revenue cycle management services to the healthcare industry. The lab will drive comprehensive automation in revenue cycle operations (15 Mar 2025, Bloomberg) 	
<h1>4</h1> <h2>Taiwan Semicon</h2>	<ul style="list-style-type: none"> Taiwan Semiconductor is down year-to-date and investors are concerned about its expansion plans (02 Apr 2025, Bloomberg) Taiwan is investigating whether China's leading chipmaker Semiconductor Manufacturing International illegally poached local engineers as part of an effort to access the island's cutting-edge chip technology (28 Mar 2025, Bloomberg) 	
<h1>5</h1> <h2>Alphabet</h2>	<ul style="list-style-type: none"> Google won a court order preventing a Russian media company from compelling the tech giant to restore its Google account, after a Russian court ordered the company to do so (02 Apr 2025, Bloomberg) Google asked a federal judge to declare that its Google Meet application doesn't infringe two patents for digital mirror technology asserted against Samsung Electronics (02 Apr 2025, Bloomberg) Alphabet's AI drug unit raises US\$600 million from OpenAI Backer (31 Mar 2025, Bloomberg) 	

Top 5 stocks traded by our customers Mar 2025

EQUITY STRATEGY TEAM

HK Market



*The Top 5 stocks are based on total traded value by OSPL customers for the month. Ranking as of 31 Mar 2025. All data and information extracted from Bloomberg as of 01 Apr 2025 closing unless otherwise stated. Trendlines drawn on price charts are a visual representation of support & resistance levels. They are drawn by connecting a series of prices together to help indicate the data's best fit or the presence of any trend over a time frame, and are for illustration purposes only.

1 Alibaba

Quick Stock Highlights

- Alibaba is planning to release Qwen 3, an upgraded version of its flagship AI model, as soon as this month with competition from rivals including OpenAI and DeepSeek heating up (01 Apr 2025, Bloomberg)
- Alibaba has released a new artificial intelligence model in its Qwen series that the company says can process text, pictures, audio and video, and is efficient enough to run directly on mobile phones and laptops (27 Mar 2025, Bloomberg)

Technical Levels & Charting



2 BYD

- BYD enjoys yet another blockbuster quarter as Tesla flounders. BYD delivered 371,419 passenger vehicles in Mar 2025, bringing the total for the first three months of the year to 986,098 units. Of those, 416,388 were pure electric vehicles (01 Apr 2025, Bloomberg)
- BYD has unveiled a new ecosystem set to allow EVs to charge for 400 kilometers in just five minutes (31 Mar 2025, Bloomberg)



3 Xiaomi

- Xiaomi confirmed that one of its SU7 electric vehicles was involved in an accident on an expressway in China. Local media reported that three people died in the incident that's likely to spark scrutiny over the smart driving software deployed in many of today's cars (01 Apr 2025, Bloomberg)
- Xiaomi just raised US\$5.5 billion, filling up a war chest for the Chinese company's aggressive expansion of its EV business (25 Mar 2025, Bloomberg)



4 Akeso

- Akeso is bringing a new treatment option for lung cancer to the US after a study showed its drug to be more effective than Merck & Co Inc.'s Keytruda. Akeso expects faster revenue growth next year after its two commercial drugs secured national insurance coverage in China (01 Apr 2025, Bloomberg)



5 Sunac China

- Sunac China might be the first developer to exit restructuring, given its ability to tap new funding and make deliveries even after default. Its HK\$1.2 billion from a share placement could pave the way for other alternatives and signal a return of market confidence, even amid a warning sign of the founder's reduced ownership. Sunac managed to deliver 58,000 houses in 1H24 and aims to deliver 170,000 units for the full year (31 Mar 2025, Bloomberg)



Disclaimer

The information provided herein is a compilation or summary of materials and data based from external sources available to OCBC Securities Private Limited ("OSPL"), and does not represent OSPL's view on the matters mentioned. Whilst we have taken all reasonable care to ensure that the information contained in this publication is not untrue or misleading at the time of publication, we cannot guarantee its accuracy or completeness, and you should not act on it without first independently verifying its contents.

Trading in capital markets products and borrowing to finance the trading transactions (including, but not limited to leveraged trading or gearing) can be very risky, and you may lose all or more than the amount invested or deposited. Where necessary, please seek advice from an independent financial adviser regarding the suitability of any trade or capital markets product taking into account your investment objectives, financial situation or particular needs before making a commitment to trade or purchase the capital markets product. In the event that you choose not to seek advice from a financial adviser, you should consider whether the capital markets product is suitable for you. You should consider carefully and exercise caution in making any trading decision whether or not you have received advice from any financial adviser. You should also read the relevant prospectus and/or profile statement (a copy of which may be obtained from the relevant fund manager or any of its approved distributors), prior to any trading or investment decision. Please refer to the prospectus of the relevant fund for the name of the fund manager and the investment objectives of the fund. In relation to collective investment schemes, the value of the units and the income accruing therefrom, if any, may rise or fall. For funds that are listed on an approved exchange, investors cannot redeem their units of those funds with the manager, or may only redeem units with the manager under certain specified conditions. The listing of the units of those funds on any approved exchange does not guarantee a liquid market for the units.

No representation or warranty whatsoever (including without limitation any representation or warranty as to accuracy, usefulness, adequacy, timeliness or completeness) in respect of any information (including without limitation any statement, figures, opinion, view or estimate) provided herein is given by OSPL and it should not be relied upon as such. OSPL does not undertake an obligation to update the information or to correct any inaccuracy that may become apparent at a later time. OSPL shall not be responsible for any loss or damage howsoever arising, directly or indirectly, as a result of any person acting on any information provided herein.

The information provided herein is intended for general circulation/discussion purposes only and may not be published or circulated in whole or in part without our written consent. All trademarks, registered trademarks, product names and company names or logos mentioned herein are the property of their respective owners, and you agree that you will not do anything to infringe or prejudice those rights. Reference to any products, services, processes or other information, does not constitute or imply endorsement, sponsorship or recommendation thereof by OSPL.

The top 5 stocks within the report are extracted based on actual data and did not go through any selection process by OCBC Securities. This information should not be viewed as advice nor recommendation. Any historical information or past performance data included in this report is not necessarily indicative of future trends or performance.

This advertisement has not been reviewed by the Monetary Authority of Singapore